Andrew D Zelenetz| - JoVE Visualize

Showing results (41-50 of 204) with videos related to

Pageof 21

Sort By:

British Journal of Haematology|December 17, 2016

Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraSantosha A Vardhana, Craig S Sauter, Matthew J Matasar, et al.

Leukemia & Lymphoma|May 24, 2011

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportThomas E Witzig, Paul Fishkin, Leo I Gordon, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008

Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe, Craig H Moskowitz, Daniel A Filippa, et al.

Clinical Lymphoma, Myeloma & Leukemia|August 18, 2020

Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell LymphomaAndrew D Zelenetz, Leslie L Popplewell, Ariela Noy, et al.

Radiology|June 3, 2015

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive LymphomaGary A Ulaner, Debra A Goldman, Craig S Sauter, et al.

British Journal of Haematology|May 15, 2009

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.

Blood|August 11, 2005

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCLCraig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.

Blood|March 16, 2002

Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphomaGouri Nanjangud, Pulivarthi H Rao, Abhijith Hegde, et al.

Cancer|September 16, 2003

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphomaEunice S Wang, David J Straus, Julie Teruya-Feldstein, et al.

Pageof 21

Showing results (41-50 of 204) with videos related to

Sort By:

Pageof 21

British Journal of Haematology|December 17, 2016

Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraSantosha A Vardhana, Craig S Sauter, Matthew J Matasar, et al.

Leukemia & Lymphoma|May 24, 2011

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportThomas E Witzig, Paul Fishkin, Leo I Gordon, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008

Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicityBradford S Hoppe, Craig H Moskowitz, Daniel A Filippa, et al.

Clinical Lymphoma, Myeloma & Leukemia|August 18, 2020

Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell LymphomaAndrew D Zelenetz, Leslie L Popplewell, Ariela Noy, et al.

Radiology|June 3, 2015

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive LymphomaGary A Ulaner, Debra A Goldman, Craig S Sauter, et al.

British Journal of Haematology|May 15, 2009

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.

Blood|August 11, 2005

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCLCraig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.

Blood|March 16, 2002

Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphomaGouri Nanjangud, Pulivarthi H Rao, Abhijith Hegde, et al.

Cancer|September 16, 2003

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphomaEunice S Wang, David J Straus, Julie Teruya-Feldstein, et al.

Pageof 21